Cancer Letters: Multi-omics immune classification reveals immunotherapy opportunities in colorectal cancer

Our team published MotifCC in Cancer Letters, a multi-omics immune classification framework for colorectal cancer that links tumor heterogeneity to prognosis and immunotherapy opportunities.

By integrating transcriptomic, mutational, and methylation features across large colorectal cancer cohorts, the study defined three immune subtypes with distinct microenvironment states and therapeutic implications. The work also supports WNT pathway inhibition as a promising strategy to sensitize immune-cold tumors to immunotherapy.

Key points:

• Built and validated a three-cluster multi-omics immune classification across large CRC cohorts.
• Identified an immune-cold subtype with strong WNT pathway activation and poor prognosis.
• Showed that WNT-targeted inhibition may help enhance antitumor immunity and improve immunotherapy response.

Paper: Multi-omics driven immune classification of colorectal cancer: Implications for immunotherapy efficacy prediction and enhancement with WNT signaling inhibition